InvestorsHub Logo
Followers 3
Posts 963
Boards Moderated 0
Alias Born 03/30/2021

Re: Kaptain78 post# 2788

Sunday, 01/30/2022 9:33:39 AM

Sunday, January 30, 2022 9:33:39 AM

Post# of 5322



"The FDA is working with Empowered Diagnostics to resolve these issues. "


Kaptain,
Those are my thoughts exactly.
AXIM was still advertising ImmunoPass on Facebook and LinkedIn with no mention of the recall issued by Empowered Diagnostics.

Meanwhile investors are watching their investment tank from $0.49 down to $0.19 on Friday. Now with the FDA release we might see single digits before this slide is over.

How is that not fraud?

In addition to that, cheap shares are the worst thing that can happen to a small company with no cashflow.

Now labor and raw materials and services like accounting and advertising all cost a lot more shares than than they did just a month ago. Can AXIM even generate enough cash to roll out the Dry Eye Disease segment now? Was Mr Huemoeller able to sell shares at $0.49 to pay for the DED roll out?

All if this stinks.
Why did Sapphire Biotech ever think it was a good idea to be bought out by MJNA leadership??

On the other hand I have always wanted to believe in Empowered Diagnostics and their leadership and yet they are the ones being called out by the FDA at this time. I just don't know if I can agree about a wink wink nod nod agreement with the FDA. However. We do have this interesting comment hidden within the FDA recall warning:

"The FDA is working with Empowered Diagnostics to resolve these issues. "


Maybe I should copy this sentence to the top so my post is not such a downer.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AXIM News